<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03817190</url>
  </required_header>
  <id_info>
    <org_study_id>DS107G-05-AD3</org_study_id>
    <nct_id>NCT03817190</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Orally Administered DS107 in Adult Patients With Moderate to Severe Atopic Dermatitis</brief_title>
  <official_title>A Randomised, Double-blind, Placebo-controlled, Study to Assess the Efficacy and Safety of Orally Administered DS107 in Adult Patients With Moderate to Severe Atopic Dermatitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>DS Biopharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>DS Biopharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to compare the efficacy and safety of orally administered
      DS107 (2g) versus placebo in the treatment of moderate to severe Atopic Dermatitis (AD).

      Oral DS107/Placebo capsules will be administered for 16 weeks. The study will enrol
      approximately 200 subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study involves a comparison of 2g DS107 with placebo, administered orally once daily for
      a total of 16 weeks. Patient will be randomized to one of the two treatment arms in a 1:1
      ratio.

      Patients will come to the clinic on 12 occasions: at Screening/Visit 1, Baseline/Visit 2,
      Week 2/Visit 3, Week 4/Visit 4, Week 6/Visit 5, Week 8/Visit 6, Week 10/Visit 7, Week
      12/Visit 8, Week 14/ Visit 9, Week 16/Visit 10 (end of treatment), Week 18/ Visit 11 (follow
      up) and Week 20/Visit 12 (follow-up).

      The primary endpoint will be the vIGA (Validated Investigator's Global Assessment) and EASI
      (Eczema Area and Severity Index). Other endpoints include vIGA, EASI, BSA (Body Surface Area)
      and NRS (Numeric Rating Scale).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 19, 2019</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">November 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Validated Investigator Global Assessment (vIGA)</measure>
    <time_frame>16 Weeks</time_frame>
    <description>Proportion of patients achieving a vIGA score of 0 (clear) or 1 (almost clear) and a decrease of at least 2 points.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Eczema Area Severity Index (EASI)</measure>
    <time_frame>16 Weeks</time_frame>
    <description>Proportion achieving EASI-75</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Validated Investigator Global Assessment (vIGA)</measure>
    <time_frame>20 Weeks</time_frame>
    <description>Proportion of patients achieving a vIGA score of 0 (clear) or 1 (almost clear) and a decrease of at least 2 points.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Eczema Area Severity Index (EASI)</measure>
    <time_frame>20 Weeks</time_frame>
    <description>Proportion achieving EASI-75</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Numeric Rating Scale (NRS)</measure>
    <time_frame>20 Weeks</time_frame>
    <description>Proportion achieving a decrease of at least 4 points</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body Surface Area</measure>
    <time_frame>Week 20</time_frame>
    <description>change from baseline</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Atopic Dermatitis</condition>
  <arm_group>
    <arm_group_label>2g Oral DS107</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2g DS107 (4 DS107 capsules) administered once-daily for 16 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo (4 placebo capsules) orally administered once-daily for 16 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DS107</intervention_name>
    <description>DS107 Capsule</description>
    <arm_group_label>2g Oral DS107</arm_group_label>
    <other_name>DGLA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo capsule</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with a clinically confirmed diagnosis of active AD according to the American
             Academy of Dermatology Consensus Criteria.

          -  Patients with moderate to severe AD at baseline as defined by a vIGA score of 3 or 4
             at baseline.

          -  Patients with an EASI score of â‰¥16 at screening and baseline.

          -  Patients with AD covering a minimum 10% of the body surface area at baseline.

        Exclusion Criteria:

          -  Patients with other skin conditions that might interfere with AD diagnosis and/or
             evaluation (such as psoriasis or current active viral, bacterial and fungal skin
             infections)

          -  Patients who have used systemic treatments that could affect AD less than 4 weeks
             prior to baseline visit (Day 0). Intranasal corticosteroids and inhaled
             corticosteroids for stable medical conditions are allowed.

          -  Patients who have used any topical medicated treatment for AD two weeks prior to start
             of treatment/ Baseline (Day 0).

          -  Patients who have had excessive sun exposure, have used tanning booths or other
             ultraviolet (UV) light sources four weeks prior to Baseline (Day 0) and/or are
             planning a trip to a sunny climate or to use tanning booths or other UV sources
             between screening and follow-up visits.

          -  Patients who have a white cell count or differential white cell count (neutrophils,
             lymphocytes, eosinophils) outside of the normal reference range at screening.

          -  Patients who have a clinically significant impairment of renal or hepatic function.

          -  Patients who are pregnant, planning pregnancy, breastfeeding and/or are unwilling to
             use adequate contraception (as specified in inclusion criterion 10) during the trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Markus Weissbach, MD</last_name>
    <role>Study Chair</role>
    <affiliation>DS Biopharma</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kirsty Kelly</last_name>
    <phone>0035312933591</phone>
    <email>k.kelly@dsbiopharma.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Moayed Hamza</last_name>
    <email>m.hamza@dsbiopharma.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>DS Investigational Site 524</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35209</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>DS107G-05-AD3@dsbiopharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>DS Investigational Site 528</name>
      <address>
        <city>Huntington Beach</city>
        <state>California</state>
        <zip>92647</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>DS107G-05-AD3@dsbiopharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>DS Investigational Site 502</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>DS107G-05-AD3@dsbiopharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>DS Investigational Site 503</name>
      <address>
        <city>Riverside</city>
        <state>California</state>
        <zip>92503</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>DS107G-05-AD3@dsbiopharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>DS Investigational Site 504</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92108</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>DS107G-05-AD3@dsbiopharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>DS Investigational Site 505</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>DS107G-05-AD3@dsbiopharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>DS Investigational Site 516</name>
      <address>
        <city>Santa Ana</city>
        <state>California</state>
        <zip>92705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>DS107G-05-AD3@dsbiopharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>DS Investigational Site 501</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>DS107G-05-AD3@dsbiopharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>DS Investigational Site 517</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20037</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>DS107G-05-AD3@dsbiopharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>DS Investigational Site 527</name>
      <address>
        <city>Doral</city>
        <state>Florida</state>
        <zip>33122</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>DS107G-05-AD3@dsbiopharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>DS Investigational Site 510</name>
      <address>
        <city>Sunrise</city>
        <state>Florida</state>
        <zip>33351</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>DS107G-05-AD3@dsbiopharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>DS Investigational Site 512</name>
      <address>
        <city>Columbus</city>
        <state>Georgia</state>
        <zip>31904</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>DS107G-05-AD3@dsbiopharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>DS Investigational Site 514</name>
      <address>
        <city>Skokie</city>
        <state>Illinois</state>
        <zip>60077</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>DS107G-05-AD3@dsbiopharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>DS Investigational Site 513</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40241</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>DS107G-05-AD3@dsbiopharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>DS Investigational Site 522</name>
      <address>
        <city>Fort Gratiot</city>
        <state>Michigan</state>
        <zip>48059</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>DS107G-05-AD3@dsbiopharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>DS Investigational Site 519</name>
      <address>
        <city>Troy</city>
        <state>Michigan</state>
        <zip>48084</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>DS107G-05-AD3@dsbiopharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>DS Investigational Site 511</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>DS107G-05-AD3@dsbiopharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>DS Investigational Site 526</name>
      <address>
        <city>Grants Pass</city>
        <state>Oregon</state>
        <zip>97527</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>DS107G-05-AD3@dsbiopharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>DS Investigational Site 521</name>
      <address>
        <city>Medford</city>
        <state>Oregon</state>
        <zip>97504</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>DS107G-05-AD3@dsbiopharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>DS Investigational Site 525</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19046</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>DS107G-05-AD3@dsbiopharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>DS Investigational Site 520</name>
      <address>
        <city>Johnston</city>
        <state>Rhode Island</state>
        <zip>02919</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>DS107G-05-AD3@dsbiopharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>DS Investigational Site 509</name>
      <address>
        <city>Arlington</city>
        <state>Texas</state>
        <zip>76011</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>DS107G-05-AD3@dsbiopharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>DS Investigational Site 506</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78745</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>DS107G-05-AD3@dsbiopharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>DS Investigational Site 508</name>
      <address>
        <city>Cypress</city>
        <state>Texas</state>
        <zip>77433</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>DS107G-05-AD3@dsbiopharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>DS Investigational Site 507</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>DS107G-05-AD3@dsbiopharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>DS Investigative Site 529</name>
      <address>
        <city>Orem</city>
        <state>Utah</state>
        <zip>84058</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>DS107G-05-AD3@dsbiopharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>DS Investigative Site 530</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84117</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>DS107G-05-AD3@dsbiopharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>DS Investigational Site 523</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>DS107G-05-AD3@dsbiopharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>DS Investigational Site 518</name>
      <address>
        <city>Kenosha</city>
        <state>Wisconsin</state>
        <zip>53144</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>DS107G-05-AD3@dsbiopharma.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>January 23, 2019</study_first_submitted>
  <study_first_submitted_qc>January 23, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 25, 2019</study_first_posted>
  <last_update_submitted>July 22, 2020</last_update_submitted>
  <last_update_submitted_qc>July 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Eczema</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

